Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonafarnib - Eiger Biopharmaceuticals

Drug Profile

Lonafarnib - Eiger Biopharmaceuticals

Alternative Names: EBP 994; MK-6336; Sarasar; SCH 066336; SCH 66336

Latest Information Update: 08 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Childrens Hospital Boston; Duke University; Eiger BioPharmaceuticals, Inc.; Merck & Co; National Institute of Diabetes and Digestive and Kidney Diseases; Schering-Plough; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors; Protein synthesis inhibitors; Squalene synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progeria; Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis D
  • Phase II Progeria
  • Discontinued Breast cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Glioma; Head and neck cancer; Leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 06 Feb 2019 Eiger Biopharmaceuticals has patents pending for lonafarnib in China and South Korea
  • 06 Feb 2019 The European Patent Office and the Japan Patent Office have issued decisions to grant patents for lonafarnib in Europe and Japan
  • 19 Dec 2018 Lonafarnib - Eiger Biopharmaceuticals receives Breakthrough Therapy status for Progeria in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top